Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$23.2K Sell
100
-65,700
-100% -$13.4M ﹤0.01% 849
2025
Q2
$12.2M Buy
65,800
+14,400
+28% +$2.68M 0.46% 40
2025
Q1
$10.8M Buy
51,400
+4,200
+9% +$816K 0.44% 48
2024
Q4
$8.39M Buy
47,200
+30,200
+178% +$5.55M 0.31% 72
2024
Q3
$3.36M Sell
17,000
-80,400
-83% -$15M 0.11% 227
2024
Q2
$16.7M Buy
97,400
+91,100
+1,446% +$15.1M 0.6% 22
2024
Q1
$1.15M Buy
+6,300
New +$1.09M 0.04% 541

Other funds holding ABBV

Point72 (DIFC)'s ABBV Position: Q3 2025 in Review

Point72 (DIFC) reduced its AbbVie (ABBV) stake by 75% in Q3 2025, selling an estimated $14.3M and leaving 23,416 shares worth $5.42M. The position accounts for 0.36% of the portfolio, ranked #72.

Point72 (DIFC) first reported a position in ABBV in Q2 2025 and has held it in 2 quarters since. The position peaked at $17.4M in Q2 2025. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Point72 (DIFC) held 23,416 shares of AbbVie worth $5.42M as of Q3 2025.
  • Point72 (DIFC) sold 70,451 AbbVie shares in Q3 2025, an estimated $14.3M.
  • AbbVie made up 0.36% of Point72 (DIFC)'s portfolio in Q3 2025, its #72 holding.
  • Point72 (DIFC) first reported a position in AbbVie in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s AbbVie position peaked at $17.4M in Q2 2025.
  • 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.